An integrated multiplatform bioanalytical strategy for antibody-drug conjugates: A novel case study

Bioanalysis

Volumn 7, Issue 13, 2015, Pages 1569-1582

  Myler, Heather ^a   Rangan, Vangipuram S ^a   Wang, Jian ^a   Kozhich, Alexander ^a   Cummings, Jennifer A ^a   Neely, Robert ^a   Dail, Donna ^a   Liu, Ang ^a   Wang, Bonnie ^b   Vezina, Heather E ^c   Freebern, Wendy ^b   Sung, Mei Chen ^a   Passmore, David ^a   Deshpande, Shrikant ^a   Kempe, Thomas ^a   Gu, Huidong ^a   Saewert, Mark ^a   Manney, Amy ^a   Lute, John ^a   Zambito, Frank ^a   Wong, Richard L ^d   Piccoli, Steven P ^a   Aubry, Anne Françoise ^a   Pillutla, Renuka ^a   Arnold, Mark ^a   DeSilva, Binodh ^a   more..

^a BRISTOL MYERS SQUIBB   (United States)

^b Drug Safety Evaluation   (United States)

^c Exploratory Clinical and Translational Research   (United States)

^d Bioanalytical Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; ANTIBODY DRUG CONJUGATE; ANTINEOPLASTIC AGENT; BIOLOGICAL PRODUCT; CATHEPSIN B; DRUG ANTIBODY; NEUTRALIZING ANTIBODY; REAGENT; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY;

ANALYTIC METHOD; ARTICLE; BIOTECHNOLOGY; CASE STUDY; DRUG DETERMINATION; DRUG SCREENING; IMMUNOGENICITY; MICROTUBULE ASSEMBLY; PHARMACOKINETICS; REPRODUCIBILITY; CASE REPORT; CHEMISTRY; HUMAN; IMMUNOLOGY;

ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOCONJUGATES;

EID: 84938411993     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.15.80     Document Type: Article

References (33)

1. Sassoon I, Blanc V. Antibody-drug conjugate (ADC) clinical pipeline: a review antibody drug conjugates. Methods Mol. Biol. 1045, 1-27 (2013
2. Tolcher AW, Ochoa L, Hammond LA et al. Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a Phase I, pharmacokinetic, and biologic correlative study. J. Clin. Oncol. 21(2), 211-222 (2003
3. Bernstein ID. Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate. Leukemia 14(3), 474-475 (2000
4. Thevanayagam L, Bell A, Chakraborty I et al. Novel detection of DNA-alkylated adducts of antibody-drug conjugates with potentially unique preclinical and biomarker applications. Bioanalysis 5(9), 1073-1081 (2013
5. Ducry L and Stump B. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjug. Chem. 21, 5-13 (2010
6. Kaur S, Xu K, Saad OM et al. Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics. Bioanalysis 5(2), 201-226 (2013
7. Gorovits B, Alley SC, Bilic S et al. 2011 Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper. Bioanalysis 5(9), 997-1006 (2013
8. Hamblett KJ, Senter PD, Chace DF et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin. Cancer Res. 10(20), 7063-7070 (2004
9. Cho H, Daniel T, Buechler YJ et al. Optimized clinical performance of growth hormone with an expanded genetic code. Proc. Natl Acad. Sci. USA 108(22), 9060-9065 (2011
10. Sukumaran S, Gadkar K, Zhang C et al. Mechanismbased pharmacokinetic/pharmacodynamic model for THIOMAB drug conjugates. Pharm. Res. doi:10.1007/ s11095-014-1582-1 (2014) (Epub ahead of print
11. Shen BQ, Xu K, Liu L et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody conjugates. Nat. Biotechnol. 30(2), 184-189 (2012
12. Lee JW, Kelley M, King LE et al. Bioanalytical approaches to quantify "total" and "free" therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug development. AAPS J. 13(1), 99-110 (2011
13. Hock MB, Thudium KE, Carrasco-Triguero M, Schwabe NF. Immunogenicity of antibody drug conjugates: bioanalytical methods and monitoring strategy for a novel therapeutic modality. AAPS J. 17(1), 35-43 (2015
14. Hoofring SA, Lopez R, Hock MB et al. Immunogenicity testing strategy and bioanalytical assays for antibody-drug conjugates. Bioanalysis 5(9), 1041-1055 (2013
15. Gorovits B, Wakshull E, Pillutla R et al. Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics. J. Immunol. Methods 408, 1-12 (2014
16. Sailstad JM, Amaravadi L, Clements-Egan A et al. A white paper-consensus and recommendations of a global harmonization team on assessing the impact of immunogenicity on pharmacokinetic measurements. AAPS J. 16(3), 488-498 (2014
17. Myler H, Felix T, Zhu J et al. Measuring biotherapeutics with endogenous counterparts and pre-existing antibodies: an interferon case study. Bioanalysis 6(8), 1113-1122 (2014
18. Myler H, Hruska MW, Srinivasan S et al. Anti- PEG antibody bioanalysis: a clinical case study with PEG-IFN-?-1a and PEG-IFN-α2a in naive patients. Bioanalysis 7(9), 1093-1106 (2015
19. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Bioanalytical Method Validation. Rockville, MD (2013). www.fda.gov
20. European Medicines Agency. Guideline on Bioanalytical Method Validation. London, England (2011). www.ema.europa.eu
21. Japan Ministry of Health and Labor Welfare. Guideline on Bioanalytical Method (Ligand Binding Assay) Validation in Pharmaceutical Development (2014). http://bcn2014.europeanbioanalysisforum.eu
22. China Pharmacopoeia (ChP). Draft Guidance on Bioanalytical Method Validation (2014). http://knex2014.europeanbioanalysisforum.eu
23. Xin Y, Xiang H, Jin D et al. 2011 Population pharmacokinetic and pharmacodynamic modeling of MNRP1685A in cynomolgus monkeys using twotarget quasi-steady-state (QSS) model. J. Pharmacokinet. Pharmacodyn. 39, 217-226 (2012
24. Gibiansky L, Gibiansky E. Target-mediated drug disposition model for drugs that bind to more than one target. J. Pharmacokinet. Pharmacodyn. 37, 323-346 (2010
25. Li L, Gardner I, Rose R, Jamei M. Incorporating target shedding into a minimal PBPK-TMDD model for monoclonal antibodies. CPT Pharmacometrics Syst. Pharmacol. 3, e96 (2014
26. Junutula JR, Raab H, Clark S et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat. Biotechnol. 26(8), 925-932 (2008
27. Gibiansky L, Gibiansky E. Target-mediated drug disposition model and its approximations for antibody-drug conjugates. J. Pharmacokinet. Pharmacodyn. 41, 35-47 (2014
28. Lu D, Gibiansky L, Jin JY et al. Integrated pharmacokinetic model for antibody-drug-conjugate (ADC) in patients with B-cell malignancy: implications for optimal sampling. J. Pharmacokinet. Pharmacodyn. 41, S44 (2014
29. Umberger TS, Sloan JH, Chen J et al. Novel sandwich immunoassays for the measurement of total and active FGF21. Bioanalysis 6(24), 3283-3293 (2014
30. Myler HA, McVay S, Kratzsch J. Troubleshooting PEG-hGH detection supporting pharmacokinetic evaluation in growth hormone deficient patients. J. Pharmacol. Toxicol. 61, 92-97 (2010
31. Myler HA, Given A, Kolz K et al. Biotherapeutic bioanalysis: a multi-indication case study review. Bioanalysis 3(6), 623-643 (2011
32. Myler HA, Phillips KR, Dong H et al. Validation and lifecycle management of a quantitative ligand-binding assay for the measurement of Nulojix®, a CTLA-4-Fc fusion protein, in renal and liver transplant patients. Bioanalysis 4(10), 1215-1226 (2012
33. Xu K, Liu L, Dere R et al. Characterization of the drug-toantibody ratio distribution for antibody-drug conjugates in plasma/serum. Bioanalysis 5(9), 1057-1071 (2013